On November 20, 10x Genomics, Inc. fell 4.27% in Pre-Market Trading, trading at $56.0 per share, with turnover of $154.2 thousand.
The move came as the market continued to digest ARK Invest's disclosed sale of 107,658 shares on November 17, while the rebound seen after that selling pressure was absorbed did not extend.
Earlier this month, 10x Genomics, Inc. reported third-quarter EPS of negative $0.15 on revenue of $150.667 million, both better than expectations, and raised full-year revenue guidance to $625 million-$635 million. Even so, post-earnings target-price cuts, including UBS lowering its target to $61 from $90 while maintaining a Neutral rating, together with the CEO's previously disclosed sale of 31,000 shares at $62.90, continued to weigh on near-term sentiment.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments